{
    "nct_id": "NCT03771157",
    "official_title": "Serologic Response to a New Recombinant, Adjuvanted Herpes Zoster Vaccine in Patients With Chronic Lymphocytic Leukemia and Waldenström Macroglobulinemia Treated With First-Line BTK Inhibitors - A Pilot Study",
    "inclusion_criteria": "* They are at least 50 years of age;\n* Have been diagnosed with chronic lymphocytic leukemia (CLL) OR Waldenström's macroglobulinemia (WM)\n* Have been on first-line BTK inhibitor (ie ibrutinib or acalabrutinib) for at least 3 months,\n* Prior treatment with single agent rituximab is permitted if last dose was administered over one year ago;\n* Have at least a one-year life expectancy;\n* Have a history of varicella (chicken-pox) OR lived in the US or any endemic country for > 30 years.\n* Prior radiation therapy is allowed\nHealthy volunteers allowed\nMust have minimum age of 50 Years",
    "exclusion_criteria": "* They have a known hypersensitivity to a vaccine component;\n* Had herpes zoster reactivation within the past year;\n* Had received or were scheduled to receive a live virus vaccine in the period from 4 weeks prior to Dose 1 through 28 days post-second dose;\n* Had received or were scheduled to receive an inactivated vaccine in the period ranging from 7 days prior to Dose 1 through 7 days post- second dose;\n* Are unable to give informed consent;\n* Have absolute lymphocyte counts greater than 20,000 X 109/L;\n* Are receiving treatment for CLL or WM with an additional agent other than a BTK inhibitor;\n* Had rituximab treatment within a year prior to study start;\n* Had prior chemotherapy.",
    "miscellaneous_criteria": ""
}